ライフサイエンスコーパス: ovarian

1 The Ovarian-Adnexal Reporting and Data System (O-RADS) US ri

2 -type-specific mechanisms underlying primate ovarian aging at single-cell resolution, revealing new d

3 e been able to disentangle chronological and ovarian aging with respect to CVD risk.

4 signaling and stimulation of apoptosis in an ovarian allograft model compared to monotherapies.

5 has established that more than one-fifth of ovarian and breast carcinomas are associated with inheri

6 significant efficacy and bioavailability in ovarian and colon cancer xenograft models when evaluated

7 creasing viability and proliferation in both ovarian and endometrial cancer cell lines.

8 .28), whereas the protective association for ovarian and endometrial cancer remained significant up t

9 ives can dramatically reduce women's risk of ovarian and endometrial cancer, whereas their effect on

10 pression signature similar to those of human ovarian and endometrial cancers.

11 accuracy in assigning risk of malignancy to ovarian and other adnexal masses, and to provide a manag

12 eceptor EphB4 is frequently overexpressed in ovarian and other solid tumors and is involved in intera

13 aphy and SPECT of patients with metastasized ovarian and pancreatic cancer for follow-up to therapy w

14 mans application was done on 2 patients with ovarian and pancreatic cancer, respectively.

15 ight samples containing known proportions of ovarian and prostate cancer tissue and yeast, or control

16 anoids, including kidney, colon, hepatocyte, ovarian, and breast.

17 orresponding associations with lung, breast, ovarian, and prostate cancer from genome-wide associatio

18 d a personal history of hereditary breast or ovarian-associated cancer.

19 impaired immune function, skewed sex ratios, ovarian atresia, reduced egg production, and altered gen

20 ovar D (UW-3/Cx) rMOMP and challenged in the ovarian bursa with serovars D (UW-3/Cx), D (UCI-96/Cx),

21 person-years at risk), 2168 women developed ovarian cancer (58 cases/100 000 person-years).

22 Epithelial ovarian cancer (EOC) is a highly lethal gynecologic mali

23 Epithelial ovarian cancer (EOC) metastasis occurs by exfoliation of

24 cles that play important roles in epithelial ovarian cancer (EOC) progression, as they are constantly

25 cer syndromes, such as hereditary breast and ovarian cancer (HBOC), consider genetic testing, especia

26 onditions-BRCA-related hereditary breast and ovarian cancer (HBOC), Lynch syndrome (LS) and familial

27 High grade serous ovarian cancer (HGSOC) is a fatal gynecologic malignancy

28 ant chemotherapy (NACT) in high-grade serous ovarian cancer (HGSOC), we performed immunogenomic analy

29 nment (TME) and ascites-derived spheroids in ovarian cancer (OC) facilitate tumor growth and progress

30 Ovarian cancer (OC) incidence and mortality rates differ

31 ed with a 2.5-fold increased risk of overall ovarian cancer (OR = 2.56; 95% CI, 1.48-4.45; P = 0.001/

32 The majority of women with recurrent ovarian cancer (OvCa) develop malignant ascites with vol

33 Ovarian cancer (OVCA) inevitably acquires resistance to

34 plicated in the progression and prognosis of ovarian cancer (OvCa).

35 retrospective cohort analyses of epithelial ovarian cancer among BRCA1/2 mutation carriers in the Co

36 A sample included 3887 women with epithelial ovarian cancer and 27 561 control individuals.

37 cluded 22 406 women with invasive epithelial ovarian cancer and 40 941 control individuals and the CI

38 ion of Gynecology and Obstetrics stage IC-IV ovarian cancer and an Eastern Cooperative Oncology Group

39 relative to the internal control miR-103a in ovarian cancer and control blood specimens collected fro

40 BRD9 is overexpressed in ovarian cancer and depleting BRD9 sensitizes cancer cell

41 of BRIP1 may confer risk for both breast and ovarian cancer and highlight the importance of functiona

42 t the RNA abundance of EIF3C is increased in ovarian cancer and positively correlates with the protei

43 pseudouridine may be a novel risk factor for ovarian cancer and that TAGs may also be important, part

44 represents a potential novel risk factor for ovarian cancer and triglycerides may be important partic

45 residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific

46 of invasive epithelial ovarian cancer in the Ovarian Cancer Association Consortium (OCAC; N = 63 347)

47 There are three types of ovarian cancer based on histopathological examination: b

48 d expression transiently increased following ovarian cancer cell detachment and in tumor cells derive

49 in vitro inhibitor of PTP4A3 and human A2780 ovarian cancer cell growth was reduced.

50 TLN1 suppresses lactotransferrin's effect on ovarian cancer cell invasion potential and proliferation

51 This TRIP-resistant ovarian cancer cell line, A2780TR, was found to be 9 tim

52 tive to TRIP compared to the wild-type A2780 ovarian cancer cell line.

53 In this study, we cultured ovarian cancer cell lines in adherent and nonadherent co

54 s9-mediated deletion of DAB2IP in epithelial ovarian cancer cell lines upregulated expression of stem

55 ivo models we show that secondary epithelial ovarian cancer cells (sEOC) do not fully reacquire the m

56 silenced, HR+, CARM1-high, high-grade serous ovarian cancer cells become PARPi sensitive, undergo mit

57 tential of Lyso-Gal for detection of primary ovarian cancer cells by using beta-gal as the biomarker.

58 , these results show that targeting FABP4 in ovarian cancer cells can inhibit their ability to adapt

59 the critical regulator of lipid responses in ovarian cancer cells cocultured with adipocytes.

60 tes binding to its cognate receptor CCR-2 on ovarian cancer cells facilitates migration and omental m

61 olecular signature of the primary epithelial ovarian cancer cells from which they are derived.

62 tor) reduced growth and peritoneal spread of ovarian cancer cells more effectively than either single

63 Here we report that ovarian cancer cells overexpressing glutaminase (GLS), a

64 nisms that govern this metastatic process in ovarian cancer cells remain poorly understood.

65 s study describes the mechanism exhibited by ovarian cancer cells required for adherent cell transiti

66 d differences in the resistance responses of ovarian cancer cells to TRIP and conventional drugs.

67 we systematically assessed in vivo growth of ovarian cancer cells, including six validated HGSC cell

68 pha mRNA and release of TNF-alpha protein in ovarian cancer cells.

69 activates the IGF1R/STAT3 signaling axis in ovarian cancer cells.

70 and inducing a metabolic shift in metastatic ovarian cancer cells.

71 ignaling and suppressed stemness features of ovarian cancer cells.

72 ne sets regulated by miR-200 in both OSE and ovarian cancer cells.

73 GLS-expressing but not in low GLS-expressing ovarian cancer cells.

74 e a vital biomarker overexpressed in primary ovarian cancer cells.

75 le for the transactivation of EGFR by LPA in ovarian cancer cells.

76 to disrupt peritoneal spread and adhesion of ovarian cancer cells.

77 ion and epithelial-mesenchymal transition of ovarian cancer cells.

78 tical inclusion cyst involvement in sporadic ovarian cancer development.

79 s fluid and tissue slices from patients with ovarian cancer facilitated characterization of patients

80 and histone modifications as "clothes of the ovarian cancer genome" in relationship to their function

81 Ovarian cancer has few known risk factors, hampering ide

82 Ovarian cancer has thus far been refractory to immunothe

83 gh-grade serous, endometrioid, or clear cell ovarian cancer in clinical complete response after a com

84 widely used as an investigation for possible ovarian cancer in symptomatic women presenting to primar

85 case-control analyses of invasive epithelial ovarian cancer in the Ovarian Cancer Association Consort

86 nts associated with hereditary breast and/or ovarian cancer in two children, a likely pathogenic vari

87 Ovarian cancer incidence was 61 cases/100 000 person-yea

88 ween the evanescent fields of microfiber and ovarian cancer inter-cellular medium at different treatm

89 etween use of powder in the genital area and ovarian cancer is not established.

90 Ovarian cancer is the fifth cause of cancer-related mort

91 efficacy of gemogenovatucel-T in front-line ovarian cancer maintenance.

92 egulation of gene signatures associated with ovarian cancer metastasis, and reduced clonogenic cancer

93 ortunity for specific metabolic targeting of ovarian cancer metastasis.

94 han in normal omentum, the preferred site of ovarian cancer metastasis.

95 ntestinal function in a preclinical model of ovarian cancer metastasis.

96 Ovarian cancer metastatic progression can be restricted

97 of this approach was further validated in an ovarian cancer model with typical germline mutations (ID

98 ns, as well as from a laying hen spontaneous ovarian cancer model.

99 PXN silencing in ovarian cancer mouse models reduced angiogenesis, tumor

100 d that targeting peritoneal LPMs may improve ovarian cancer outcomes.

101 ue of 53 U/ml equated to a 3% probability of ovarian cancer overall.

102 HE4 and IL8 levels positively correlated in ovarian cancer patient tissue.

103 High-grade serous ovarian cancer patient tumors and cells express signific

104 A germline BRCA mutation (BRCAm) in ovarian cancer patients provides prognostic and predicti

105 expressed in high-grade serous carcinoma of ovarian cancer patients, and its expression is even high

106 of ~6,000 FTE cells, predominantly from non-ovarian cancer patients, identified 6 FTE subtypes.

107 LPA), a lipid mediator present in ascites of ovarian cancer patients, induced expression of TNF-alpha

108 tes with the protein expression of YTHDF1 in ovarian cancer patients, suggesting modification of EIF3

109 arget of MCP-1/CCR-2 axis that could benefit ovarian cancer patients.

110 n can be an effective therapeutic target for ovarian cancer prevention or treatment.

111 cin 1 (uMUC1) tumor antigen, a biomarker for ovarian cancer progression and response to therapy, usin

112 ate ovarian cancer stem cells and to prevent ovarian cancer recurrence.

113 Ovarian cancer remains a significant challenge in women

114 emerging paradigm is changing many facets of ovarian cancer research and routine gynecology practice.

115 -onset breast cancer and 1,199 patients with ovarian cancer revealed nearly 2% of patients carry a ve

116 ductase inhibition was associated with lower ovarian cancer risk (hazard ratio, 0.69 [95% CI, 0.51-0.

117 n ever use of powder in the genital area and ovarian cancer risk among women with a patent reproducti

118 relationship between incessant ovulation and ovarian cancer risk in order to identify mechanisms of c

119 vulatory cycles (LOC) and its components and ovarian cancer risk overall and by histotype.

120 hemopreventive role of statins in epithelial ovarian cancer risk.

121 rol study within the United Kingdom Trial of Ovarian Cancer Screening (UKCTOCS).

122 Ovarian cancer selective metastasizes to the omentum con

123 d with clear cell, endometrioid, or mucinous ovarian cancer should be offered somatic tumor testing f

124 All women diagnosed with epithelial ovarian cancer should have germline genetic testing for

125 s to neoadjuvant chemotherapy for epithelial ovarian cancer should not be used as individual predicti

126 Atlas (TCGA) database and in residual human ovarian cancer specimens after chemotherapy.

127 way inhibitor has the potential to eradicate ovarian cancer stem cells and to prevent ovarian cancer

128 though the MEK Inhibitor in Low-Grade Serous Ovarian Cancer Study did not meet its primary end point,

129 State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based re-treatment

130 rmline genetic testing for BRCA1/2 and other ovarian cancer susceptibility genes.

131 of N-glycans from human laryngeal cancer and ovarian cancer tissues.

132 limited efficacy of tocilizumab observed in ovarian cancer to date.

133 Yet the antioxidant adaptations required for ovarian cancer transcoelomic metastasis, which is the pa

134 itaxel resistance is a critical challenge in ovarian cancer treatment.

135 sm gene sets were strongly correlated in the ovarian cancer Tumor Cancer Genome Atlas (TCGA) database

136 Advanced ovarian cancer usually spreads to the omentum.

137 ond-degree blood relatives of a patient with ovarian cancer with a known germline pathogenic cancer s

138 2 mAb, also mediated improved survival in an ovarian cancer xenograft model.

139 A panel of patient-derived ovarian cancer xenografts (PDX), similar in genetics and

140 le breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI

141 ho were aged >=50 years and who did not have ovarian cancer, 20.4% were diagnosed with a non-ovarian

142 , when monoallelic, predispose to breast and ovarian cancer, and when biallelic, result in a severe s

143 how a unique collagen fragment may regulate ovarian cancer, but in addition may help provide a usefu

144 n extremely high lifetime risk of breast and ovarian cancer, but the exact mechanism by which the BRC

145 In a mouse model of metastatic ovarian cancer, fluorescently labeled silica, poly(lacti

146 etabolites (N = 420) with risk of epithelial ovarian cancer, including both borderline and invasive t

147 tivity occurs in multiple cancers, including ovarian cancer, medulloblastoma, breast cancer, colorect

148 ade serous carcinoma (HGSC), the most common ovarian cancer, posits to its development in fallopian t

149 In a mouse model of non-resectable ovarian cancer, the cell-loaded nitinol thin films spati

150 Novel therapies are urgently needed for ovarian cancer, the deadliest gynecologic malignancy.

151 g for all women with non-mucinous epithelial ovarian cancer, there is significant variability in acce

152 l carcinoma (OCCC), a challenging subtype of ovarian cancer, this problem is compounded by near-unive

153 ioritize potential points of intervention in ovarian cancer, we identified the lysine rich coiled-coi

154 ulatory elements influence predisposition to ovarian cancer, we used motifbreakR to predict the disru

155 egimens in the management of newly diagnosed ovarian cancer.

156 ostic significance in patients with advanced ovarian cancer.

157 ood biomarkers for both human and laying hen ovarian cancer.

158 opens the door to targeted immunotherapy for ovarian cancer.

159 novel therapies for this aggressive form of ovarian cancer.

160 kinase AXL to induce oncogenic signaling in ovarian cancer.

161 biopsies from patients with glioblastoma and ovarian cancer.

162 buting to the poor prognosis associated with ovarian cancer.

163 bine in platinum-resistant high-grade serous ovarian cancer.

164 imens from 20 human patients with epithelial ovarian cancer.

165 ty of people with colorectal, endometrial or ovarian cancer.

166 kly treatment among patients with epithelial ovarian cancer.

167 me stability underlies hereditary breast and ovarian cancer.

168 tly associated with lower odds of epithelial ovarian cancer.

169 ncer phenotype, is the most common malignant ovarian cancer.

170 alpha to regulate an inflammatory network in ovarian cancer.

171 -200 (miR-200) family is highly expressed in ovarian cancer.

172 rian cancer, 20.4% were diagnosed with a non-ovarian cancer.

173 h newly diagnosed, advanced-stage epithelial ovarian cancer.

174 facilitating tumorigenesis and metastasis of ovarian cancer.

175 oinciding with poor outcome in patients with ovarian cancer.

176 vel EphB4-based therapeutic approach against ovarian cancer.

177 tment option for platinum-eligible recurrent ovarian cancer.

178 -emitting radionuclides for the treatment of ovarian cancer.

179 72-positive xenografts in a murine model of ovarian cancer.

180 ic cytokines and chemokines overexpressed in ovarian cancer.

181 genesis and altered immunogenic responses in ovarian cancer.

182 sk, ranges from 12 for testicular to 2.5 for ovarian cancer.

183 f the AXL signaling axis in PIK3R2-amplified ovarian cancer.

184 xt-specific, pro-metastatic role of SIRT3 in ovarian cancer.

185 compared with breast, prostate, uterine, and ovarian cancer.

186 aged <50 years and 15.2% aged >=50 years had ovarian cancer.

187 the genital area and self-reported incident ovarian cancer.

188 in the PLCO (Prostate, Lung, Colorectal, and Ovarian) Cancer Screening Trial (n = 41 856).

189 fficacy in triple negative breast (TNBC) and ovarian cancers (OCs) harboring BRCA mutations, generati

190 Advanced ovarian cancers are a leading cause of cancer-related de

191 y exerting synergistic anti-tumor effects on ovarian cancers with PTEN deficiency and KRAS(G12D) muta

192 ovel congeners in triple negative breast and ovarian cancers, malignancies that typically succumb to

193 ignancies, such as cervical, endometrial and ovarian cancers, through direct and indirect mechanisms,

194 ncing antitumor efficacy in breast, lung and ovarian cancers.

195 primarily associate with familial breast and ovarian cancers.

196 riguing link between incessant ovulation and ovarian carcinogenesis.

197 Endometrioid ovarian carcinoma (EnOC) demonstrates substantial clinic

198 on in the heterogeneity of high-grade serous ovarian carcinoma (HGSC), we perform mass spectrometry-b

199 High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecologic

200 High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecologic

201 transcriptome subtypes of high-grade serous ovarian carcinoma (HGSOC), but their interpretation and

202 Ovarian carcinoma (OvC) remains a major therapeutic chal

203 h a markedly different integrin fingerprint: ovarian carcinoma A2780 (almost no alpha(v)beta(3), mode

204 minal helicase 1 (BRIP1) are associated with ovarian carcinoma and may also contribute to breast canc

205 o ferroptosis sensitivity in human renal and ovarian carcinoma cells.

206 High-grade serous ovarian carcinoma is characterised by TP53 mutation and

207 Epithelial ovarian carcinoma tissues express high levels of tumor n

208 Patients with platinum-sensitive, recurrent ovarian carcinoma were randomly assigned to rucaparib (6

209 a group of ~30 cancer cells from a recurrent ovarian carcinoma.

210 le structures and developed low-grade serous ovarian carcinomas with 100% penetrance within 18 weeks.

211 ressed in many cancers, including breast and ovarian carcinomas.

212 ous carcinoma, accounts for up to 70% of all ovarian cases.

213 that the growth of the widely used non-HGSC ovarian cell line SKOV3 could be significantly improved

214 Although different ovarian cell types have been identified through traditio

215 n-human primates (NHPs) and identified seven ovarian cell types with distinct gene-expression signatu

216 rovides the whole transcriptome landscape of ovarian cells and unearths new insights during primordia

217 Ovarian clear cell adenocarcinoma (OCCA) is characterize

218 In ovarian clear cell carcinoma (OCCC), a challenging subty

219 of clonal populations from a patient-derived ovarian clear cell carcinoma model which forms malignant

220 at putative oogonial stem cells exist in the ovarian cortex and that these can be captured by DDX4 an

221 files of over 24,000 cells from high quality ovarian cortex samples from 21 patients.

222 FTO inhibited the self-renewal of ovarian CSC and suppressed tumorigenesis in vivo, both o

223 s were verified in both human and laying hen ovarian cysts and tumor specimens.

224 Furthermore, ovarian-derived hormones were necessary for and sufficie

225 ption factors SRY and SOX9 in XY gonads, and ovarian differentiation involves R-spondin1 (RSPO1) medi

226 al therapeutic targets for age-related human ovarian disorders.

227 The ovarian dose model is preferred if ovarian radiation dos

228 8) and AP of 0.68 (95% CI 0.53-0.81) for the ovarian dose model, and AUC of 0.96 (0.94-0.97) and AP o

229 , in which all primary tumors arise de novo, ovarian epithelial cancers are primarily imported from e

230 ereas females were protected irrespective of ovarian estrogen, in this study, we show that males accu

231 regulating the ovarian function as key intra-ovarian factors.

232 Both acute ovarian failure risk prediction models performed well.

233 his cohort study, prediction models of acute ovarian failure risk were developed using eligible femal

234 %) of analysed SJLIFE participants had acute ovarian failure.

235 in ovarian transcriptomes and reductions in ovarian follicle density between juvenile alligators fro

236 gonadotropins exhibit normal distribution of ovarian follicles and corpora lutea.

237 melatonin does not confer the protection of ovarian follicles, either directly or indirectly.

238 , and evolutionary conservation of mammalian ovarian follicles.

239 growth factors implicated in regulating the ovarian function as key intra-ovarian factors.

240 est irradiated survivors, and the effects of ovarian function on breast cancer risk.

241 erived not only from PDAC, but also bladder, ovarian, gastric, lung, and basal-like breast cancers.

242 Here, we show that PHF7-expressing ovarian germ cells inappropriately express hundreds of g

243 from the prediction analysis if they had an ovarian hormone deficiency, had missing exposure informa

244 fectiveness of nicotine in female rats in an ovarian hormone-dependent manner.

245 n a sex-specific manner and demonstrate that ovarian hormones are necessary for the prophylactic effi

246 les were also included to assess the role of ovarian hormones in promoting nicotine reinforcement.

247 with differential sensitivity to circulating ovarian hormones.

248 molecular mechanism of HSF2BP-S167L in human ovarian insufficiency and sub(in)fertility.

249 een anti-KHDC3L autoantibodies and premature ovarian insufficiency, and between anti-RFX6 autoantibod

250 CM8-9, a helicase complex mutated in primary ovarian insufficiency, and RPA1.

251 Results A total of 79 ovarian lesions in 58 women (mean age +/- standard devia

252 s MRI in discriminating benign and malignant ovarian lesions.

253 ped ovarian neoplasms that were derived from ovarian luteal cells.

254 and the eyestalk ablation in the process of ovarian maturation in black tiger shrimp suggest that wi

255 mors, all PGRB-overexpressing mice developed ovarian neoplasms that were derived from ovarian luteal

256 fining a genotypic-phenotypic correlation in ovarian neoplasms.

257 aling has the potential to permanently alter ovarian organization and function.

258 Among 148 patients with mesothelioma or ovarian, pancreatic, non-small-cell lung, and breast can

259 To examine the role of ZIP9 in ovarian physiology, we generated a ZIP9-mutant zebrafish

260 enesis and play central roles in controlling ovarian physiology.

261 rols from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

262 sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma

263 ewish ancestry and family history of breast, ovarian, prostate, or pancreatic cancer.

264 The ovarian dose model is preferred if ovarian radiation dosimetry is available.

265 ata on gynecologic history with levels of an ovarian reserve marker (anti-mullerian hormone [AMH)] to

266 ng perinatal ages and largely determines the ovarian reserve that will be available to support the re

267 depends on the size and quality of a finite ovarian reserve.

268 esulting in rapid, reversible suppression of ovarian sex hormones, may reduce fibroid-associated blee

269 ly expressed in immune cells (hemocytes) and ovarian somatic cells (stretched cells) during their bri

270 These studies provide insights into ovarian somatic cells and a resource to study the develo

271 hPGCLCs are aggregated with mouse embryonic ovarian somatic cells to form xenogeneic reconstituted o

272 ignatures, including oocyte and six types of ovarian somatic cells.

273 ve patient derived xenograft (PDX) models of ovarian (ST070), endometrial (ST040) and triple negative

274 g exposure information, or had indeterminate ovarian status.

275 e characteristics of lipid droplets (LDs) in ovarian steroidogenic cells.

276 ies speak to the epigenetic factors by which ovarian steroids produce negative behavioral effects.

277 ESC/E(Z) complex, an effector of response to ovarian steroids.

278 We refined ovarian stimulation and in vitro fertilization (IVF) met

279 lial pregranulosa (EPG) cells, arises in the ovarian surface epithelium, ingresses cortically by E12.

280 ted physiological cultures of HeLa cells and ovarian tissues in vitro, with superior outcomes than st

281 , genetic ablation of Sox8 and Sox9 prevents ovarian-to-testicular reprogramming observed in XX Rspo1

282 observed broad site-of-origin divergence in ovarian transcriptomes and reductions in ovarian follicl

283 The ovarian tumor (OTU) family of deubiquitinases regulates

284 The ovarian tumor (OTU) subfamily deubiquitinases have been

285 opean-based, algorithmic-style International Ovarian Tumor Analysis (IOTA) Assessment of Different Ne

286 Wnt5a promoted ovarian tumor cell adhesion to peritoneal mesothelial ce

287 nsequences of ascites-induced compression on ovarian tumor cells and components of the peritoneal mic

288 ide that selectively binds integrin beta3 on ovarian tumor cells enhances the phosphorylation of the

289 ncer cells and has beneficial effects on the ovarian tumor immune microenvironment.

290 a useful new alternative strategy to control ovarian tumor progression based on selectively disruptin

291 lomavirus-induced chromosomal alterations in ovarian tumorigenesis, and they add new genes to known c

292 we show that FTO expression is suppressed in ovarian tumors and cancer stem cells (CSC).

293 Transcriptomic analyses of the ovarian tumors from PGRB-overexpressing mice revealed en

294 y be important particularly in rapidly fatal ovarian tumors.

295 deficiency is exploited to treat breast and ovarian tumors.

296 hology and transcriptome analysis on a large ovarian tumour cohort and develop a machine learning app

297 accumulation in tumours and strongly reduces ovarian tumour progression in mice.

298 o find that peritoneal LPMs infiltrate early ovarian tumours and that RXR deletion diminishes LPM acc

299 In 21 cases of borderline ovarian tumours, of which 11 were regarded as malignant

300 t, to differentiate borderline and malignant ovarian tumours.